Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $3.8 million.

  • Kiniksa Pharmaceuticals International's Gains from Investment Securities rose 3793000.0% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 5826.41%. This contributed to the annual value of $9.7 million for FY2024, which is 1607.1% down from last year.
  • Kiniksa Pharmaceuticals International's Gains from Investment Securities amounted to $3.8 million in Q3 2025, which was up 3793000.0% from $1000.0 recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Gains from Investment Securities peaked at $10.0 million during Q2 2023, and registered a low of -$3.3 million during Q1 2023.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Gains from Investment Securities had a median value of $1.3 million in 2022 and averaged $2.1 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Gains from Investment Securities tumbled by 129264.07% in 2022, and later soared by 3793000.0% in 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Gains from Investment Securities (Quarter) stood at $4.9 million in 2021, then rose by 23.35% to $6.1 million in 2022, then crashed by 121.58% to -$1.3 million in 2023, then soared by 292.38% to $2.5 million in 2024, then surged by 50.67% to $3.8 million in 2025.
  • Its Gains from Investment Securities stands at $3.8 million for Q3 2025, versus $1000.0 for Q2 2025 and $3.0 million for Q1 2025.